BioMarin Pharmaceutical Inc.NASDAQ: BMRN

BioMarin Announces Fourth Quarter and Record Full-year 2019 Financial Results

· Issued by BioMarin Pharmaceutical Inc.

- Full-year 2019 Total Revenues Increased 14% to $1.7 billion

- 17% Increase in Net Product Revenues from Products Marketed by BioMarin to $1.6 billion in Full-year 2019

- 2020 Full-year Total Revenue Growth Expected to be Between 14% and 20%

- For the Full-year 2020 BioMarin Expects for the First Time to be Profitable on a GAAP Basis

- U.S. and European Marketing Submissions for Valoctocogene Roxaparvovec for Severe Hemophilia A Accepted by FDA and EMA under Priority Review and Accelerated Assessment, Respectively; Approval Decisions Expected in Second Half of 2020

- Phase 3 Study with Vosoritide for Achondroplasia Demonstrated Highly Statistically Significant Increase (p

BioMarin Pharmaceutical Inc. on 6ix

Story so far

Earlier from BioMarin Pharmaceutical

Later from BioMarin Pharmaceutical

All BioMarin Pharmaceutical news releases